Hospital-Acquired Infection Diagnostics Market By Product (Instrument, Reagents and Consumables), By Test Type (Molecular Diagnostics, Immunoassay, Others), By Application (Disease Testing, Drug-Resistance Testing), By Infection Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections (UTI), Others), By End User (Hospital, Standalone Laboratories, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global hospital acquired infection diagnostics market was valued $3,355.28 million in 2020 and expected to reach $6,983.75 million by 2030, with a CAGR of 7.6% from 2021 to 2030.
Hospital-acquired illnesses, known as nosocomial infections, are infections acquired while in the hospital. Infections can be contracted at a hospital, nursing home, rehabilitation center, outpatient clinic, or other therapeutic setting. They can be obtained via an infected patient, the outside environment, or the facility's staff. The development in awareness among healthcare professionals and proposed government initiatives by several governmental organizations drive the growth of hospital-acquired infection diagnostics market. Furthermore, sanitation and hygiene are at a minimum in growing economies such as China, India, and Brazil. As a result, there are more hospital-acquired illnesses, driving up need for hospital-acquired infection diagnostics.
The expanding elderly population base, demand for HAI diagnostics from middle and low-income nations, and development of technologically improved diagnostic tools are all factors that drive the HAI diagnostics markets. Furthermore, the development of technologically improved diagnostic products that provide accurate and dependable results in a short amount of time is beneficial. The advancement of molecular diagnostics is being funded by major corporations. Many awareness campaigns have been launched by various governments and nonprofit organizations to reduce the number of people who die as a result of HAI, which is projected to create enough chances for the HAI diagnostics market to expand. The World Health Organization (WHO) launched a public awareness campaign called Patient Safety Solutions, in which the WHO emphasized hand hygiene as a top priority for health care facilities in order to reduce the number of infections.
The hospital-acquired infection diagnostics market is segmented on the basis of product, test type, application, infection type, end user, and region. By product, the industry is split into instrument & reagents and consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By application type, the market is bifurcated into disease testing and drug resistance testing.
Furthermore, by infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. Its end users include hospitals, clinics, ambulatory surgery centers (ASC), and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global hospital acquired infection diagnostics market are Abbott, Bayer, Becton Dickinson & Company, Danaher Corporation, Ecolab, Hologic, Johnson & Johnson, Merck Kgaa, Pfizer and Steris PLC.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hospital-acquired infection diagnostics market analysis from 2020 to 2030 to identify the prevailing hospital-acquired infection diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hospital-acquired infection diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hospital-acquired infection diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Instrument
Reagents and Consumables
By Test Type
Molecular Diagnostics
Immunoassay
Others
By Application
Disease Testing
Drug-Resistance Testing
By Infection Type
Hospital Acquired Pneumonia
Bloodstream Infections
Surgical Site Infections
Gastrointestinal Infections
Urinary Tract Infections (UTI)
Others
By End User
Hospital
Standalone Laboratories
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of LAMEA
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
ABBOTT LABORATORIES
ECOLAB
JOHNSON & JOHNSON
MERCK KGaA
BAYER SCHERING PHARMA LLC
BECTON DICKINSON AND COMPANY
PFIZER INC.
STERIS PLC
HOLOGIC, INC.
DANAHER CORPORATION
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Instrument
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Reagents and Consumables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Molecular Diagnostics
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Immunoassay
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Disease Testing
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Drug-Resistance Testing
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Hospital Acquired Pneumonia
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Bloodstream Infections
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Surgical Site Infections
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
- 7.5 Gastrointestinal Infections
- 7.5.1 Key market trends, growth factors and opportunities
- 7.5.2 Market size and forecast, by region
- 7.5.3 Market analysis by country
- 7.6 Urinary Tract Infections (UTI)
- 7.6.1 Key market trends, growth factors and opportunities
- 7.6.2 Market size and forecast, by region
- 7.6.3 Market analysis by country
- 7.7 Others
- 7.7.1 Key market trends, growth factors and opportunities
- 7.7.2 Market size and forecast, by region
- 7.7.3 Market analysis by country
- CHAPTER 8: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 Hospital
- 8.2.1 Key market trends, growth factors and opportunities
- 8.2.2 Market size and forecast, by region
- 8.2.3 Market analysis by country
- 8.3 Standalone Laboratories
- 8.3.1 Key market trends, growth factors and opportunities
- 8.3.2 Market size and forecast, by region
- 8.3.3 Market analysis by country
- 8.4 Others
- 8.4.1 Key market trends, growth factors and opportunities
- 8.4.2 Market size and forecast, by region
- 8.4.3 Market analysis by country
- CHAPTER 9: HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY REGION
- 9.1 Overview
- 9.1.1 Market size and forecast
- 9.2 North America
- 9.2.1 Key trends and opportunities
- 9.2.2 North America Market size and forecast, by By Product
- 9.2.3 North America Market size and forecast, by By Test Type
- 9.2.4 North America Market size and forecast, by By Application
- 9.2.5 North America Market size and forecast, by By Infection Type
- 9.2.6 North America Market size and forecast, by End User
- 9.2.7 North America Market size and forecast, by country
- 9.2.7.1 U.S.
- 9.2.7.1.1 Market size and forecast, by By Product
- 9.2.7.1.2 Market size and forecast, by By Test Type
- 9.2.7.1.3 Market size and forecast, by By Application
- 9.2.7.1.4 Market size and forecast, by By Infection Type
- 9.2.7.1.5 Market size and forecast, by End User
- 9.2.7.2 Canada
- 9.2.7.2.1 Market size and forecast, by By Product
- 9.2.7.2.2 Market size and forecast, by By Test Type
- 9.2.7.2.3 Market size and forecast, by By Application
- 9.2.7.2.4 Market size and forecast, by By Infection Type
- 9.2.7.2.5 Market size and forecast, by End User
- 9.2.7.3 Mexico
- 9.2.7.3.1 Market size and forecast, by By Product
- 9.2.7.3.2 Market size and forecast, by By Test Type
- 9.2.7.3.3 Market size and forecast, by By Application
- 9.2.7.3.4 Market size and forecast, by By Infection Type
- 9.2.7.3.5 Market size and forecast, by End User
- 9.3 Europe
- 9.3.1 Key trends and opportunities
- 9.3.2 Europe Market size and forecast, by By Product
- 9.3.3 Europe Market size and forecast, by By Test Type
- 9.3.4 Europe Market size and forecast, by By Application
- 9.3.5 Europe Market size and forecast, by By Infection Type
- 9.3.6 Europe Market size and forecast, by End User
- 9.3.7 Europe Market size and forecast, by country
- 9.3.7.1 Germany
- 9.3.7.1.1 Market size and forecast, by By Product
- 9.3.7.1.2 Market size and forecast, by By Test Type
- 9.3.7.1.3 Market size and forecast, by By Application
- 9.3.7.1.4 Market size and forecast, by By Infection Type
- 9.3.7.1.5 Market size and forecast, by End User
- 9.3.7.2 France
- 9.3.7.2.1 Market size and forecast, by By Product
- 9.3.7.2.2 Market size and forecast, by By Test Type
- 9.3.7.2.3 Market size and forecast, by By Application
- 9.3.7.2.4 Market size and forecast, by By Infection Type
- 9.3.7.2.5 Market size and forecast, by End User
- 9.3.7.3 U.K.
- 9.3.7.3.1 Market size and forecast, by By Product
- 9.3.7.3.2 Market size and forecast, by By Test Type
- 9.3.7.3.3 Market size and forecast, by By Application
- 9.3.7.3.4 Market size and forecast, by By Infection Type
- 9.3.7.3.5 Market size and forecast, by End User
- 9.3.7.4 Italy
- 9.3.7.4.1 Market size and forecast, by By Product
- 9.3.7.4.2 Market size and forecast, by By Test Type
- 9.3.7.4.3 Market size and forecast, by By Application
- 9.3.7.4.4 Market size and forecast, by By Infection Type
- 9.3.7.4.5 Market size and forecast, by End User
- 9.3.7.5 Spain
- 9.3.7.5.1 Market size and forecast, by By Product
- 9.3.7.5.2 Market size and forecast, by By Test Type
- 9.3.7.5.3 Market size and forecast, by By Application
- 9.3.7.5.4 Market size and forecast, by By Infection Type
- 9.3.7.5.5 Market size and forecast, by End User
- 9.3.7.6 Rest of Europe
- 9.3.7.6.1 Market size and forecast, by By Product
- 9.3.7.6.2 Market size and forecast, by By Test Type
- 9.3.7.6.3 Market size and forecast, by By Application
- 9.3.7.6.4 Market size and forecast, by By Infection Type
- 9.3.7.6.5 Market size and forecast, by End User
- 9.4 Asia-Pacific
- 9.4.1 Key trends and opportunities
- 9.4.2 Asia-Pacific Market size and forecast, by By Product
- 9.4.3 Asia-Pacific Market size and forecast, by By Test Type
- 9.4.4 Asia-Pacific Market size and forecast, by By Application
- 9.4.5 Asia-Pacific Market size and forecast, by By Infection Type
- 9.4.6 Asia-Pacific Market size and forecast, by End User
- 9.4.7 Asia-Pacific Market size and forecast, by country
- 9.4.7.1 Japan
- 9.4.7.1.1 Market size and forecast, by By Product
- 9.4.7.1.2 Market size and forecast, by By Test Type
- 9.4.7.1.3 Market size and forecast, by By Application
- 9.4.7.1.4 Market size and forecast, by By Infection Type
- 9.4.7.1.5 Market size and forecast, by End User
- 9.4.7.2 China
- 9.4.7.2.1 Market size and forecast, by By Product
- 9.4.7.2.2 Market size and forecast, by By Test Type
- 9.4.7.2.3 Market size and forecast, by By Application
- 9.4.7.2.4 Market size and forecast, by By Infection Type
- 9.4.7.2.5 Market size and forecast, by End User
- 9.4.7.3 Australia
- 9.4.7.3.1 Market size and forecast, by By Product
- 9.4.7.3.2 Market size and forecast, by By Test Type
- 9.4.7.3.3 Market size and forecast, by By Application
- 9.4.7.3.4 Market size and forecast, by By Infection Type
- 9.4.7.3.5 Market size and forecast, by End User
- 9.4.7.4 India
- 9.4.7.4.1 Market size and forecast, by By Product
- 9.4.7.4.2 Market size and forecast, by By Test Type
- 9.4.7.4.3 Market size and forecast, by By Application
- 9.4.7.4.4 Market size and forecast, by By Infection Type
- 9.4.7.4.5 Market size and forecast, by End User
- 9.4.7.5 South Korea
- 9.4.7.5.1 Market size and forecast, by By Product
- 9.4.7.5.2 Market size and forecast, by By Test Type
- 9.4.7.5.3 Market size and forecast, by By Application
- 9.4.7.5.4 Market size and forecast, by By Infection Type
- 9.4.7.5.5 Market size and forecast, by End User
- 9.4.7.6 Rest of LAMEA
- 9.4.7.6.1 Market size and forecast, by By Product
- 9.4.7.6.2 Market size and forecast, by By Test Type
- 9.4.7.6.3 Market size and forecast, by By Application
- 9.4.7.6.4 Market size and forecast, by By Infection Type
- 9.4.7.6.5 Market size and forecast, by End User
- 9.5 LAMEA
- 9.5.1 Key trends and opportunities
- 9.5.2 LAMEA Market size and forecast, by By Product
- 9.5.3 LAMEA Market size and forecast, by By Test Type
- 9.5.4 LAMEA Market size and forecast, by By Application
- 9.5.5 LAMEA Market size and forecast, by By Infection Type
- 9.5.6 LAMEA Market size and forecast, by End User
- 9.5.7 LAMEA Market size and forecast, by country
- 9.5.7.1 Brazil
- 9.5.7.1.1 Market size and forecast, by By Product
- 9.5.7.1.2 Market size and forecast, by By Test Type
- 9.5.7.1.3 Market size and forecast, by By Application
- 9.5.7.1.4 Market size and forecast, by By Infection Type
- 9.5.7.1.5 Market size and forecast, by End User
- 9.5.7.2 Saudi Arabia
- 9.5.7.2.1 Market size and forecast, by By Product
- 9.5.7.2.2 Market size and forecast, by By Test Type
- 9.5.7.2.3 Market size and forecast, by By Application
- 9.5.7.2.4 Market size and forecast, by By Infection Type
- 9.5.7.2.5 Market size and forecast, by End User
- 9.5.7.3 South Africa
- 9.5.7.3.1 Market size and forecast, by By Product
- 9.5.7.3.2 Market size and forecast, by By Test Type
- 9.5.7.3.3 Market size and forecast, by By Application
- 9.5.7.3.4 Market size and forecast, by By Infection Type
- 9.5.7.3.5 Market size and forecast, by End User
- 9.5.7.4 Rest of LAMEA
- 9.5.7.4.1 Market size and forecast, by By Product
- 9.5.7.4.2 Market size and forecast, by By Test Type
- 9.5.7.4.3 Market size and forecast, by By Application
- 9.5.7.4.4 Market size and forecast, by By Infection Type
- 9.5.7.4.5 Market size and forecast, by End User
- CHAPTER 10: COMPANY LANDSCAPE
- 10.1. Introduction
- 10.2. Top winning strategies
- 10.3. Product Mapping of Top 10 Player
- 10.4. Competitive Dashboard
- 10.5. Competitive Heatmap
- 10.6. Key developments
- CHAPTER 11: COMPANY PROFILES
- 11.1 ABBOTT LABORATORIES
- 11.1.1 Company overview
- 11.1.2 Company snapshot
- 11.1.3 Operating business segments
- 11.1.4 Product portfolio
- 11.1.5 Business performance
- 11.1.6 Key strategic moves and developments
- 11.2 ECOLAB
- 11.2.1 Company overview
- 11.2.2 Company snapshot
- 11.2.3 Operating business segments
- 11.2.4 Product portfolio
- 11.2.5 Business performance
- 11.2.6 Key strategic moves and developments
- 11.3 JOHNSON & JOHNSON
- 11.3.1 Company overview
- 11.3.2 Company snapshot
- 11.3.3 Operating business segments
- 11.3.4 Product portfolio
- 11.3.5 Business performance
- 11.3.6 Key strategic moves and developments
- 11.4 MERCK KGaA
- 11.4.1 Company overview
- 11.4.2 Company snapshot
- 11.4.3 Operating business segments
- 11.4.4 Product portfolio
- 11.4.5 Business performance
- 11.4.6 Key strategic moves and developments
- 11.5 BAYER SCHERING PHARMA LLC
- 11.5.1 Company overview
- 11.5.2 Company snapshot
- 11.5.3 Operating business segments
- 11.5.4 Product portfolio
- 11.5.5 Business performance
- 11.5.6 Key strategic moves and developments
- 11.6 BECTON DICKINSON AND COMPANY
- 11.6.1 Company overview
- 11.6.2 Company snapshot
- 11.6.3 Operating business segments
- 11.6.4 Product portfolio
- 11.6.5 Business performance
- 11.6.6 Key strategic moves and developments
- 11.7 PFIZER INC.
- 11.7.1 Company overview
- 11.7.2 Company snapshot
- 11.7.3 Operating business segments
- 11.7.4 Product portfolio
- 11.7.5 Business performance
- 11.7.6 Key strategic moves and developments
- 11.8 STERIS PLC
- 11.8.1 Company overview
- 11.8.2 Company snapshot
- 11.8.3 Operating business segments
- 11.8.4 Product portfolio
- 11.8.5 Business performance
- 11.8.6 Key strategic moves and developments
- 11.9 HOLOGIC, INC.
- 11.9.1 Company overview
- 11.9.2 Company snapshot
- 11.9.3 Operating business segments
- 11.9.4 Product portfolio
- 11.9.5 Business performance
- 11.9.6 Key strategic moves and developments
- 11.10 DANAHER CORPORATION
- 11.10.1 Company overview
- 11.10.2 Company snapshot
- 11.10.3 Operating business segments
- 11.10.4 Product portfolio
- 11.10.5 Business performance
- 11.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)
- TABLE 2. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR INSTRUMENT, BY REGION , 2020-2030,($MILLION)
- TABLE 3. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET INSTRUMENT BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR REAGENTS AND CONSUMABLES, BY REGION , 2020-2030,($MILLION)
- TABLE 5. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REAGENTS AND CONSUMABLES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)
- TABLE 7. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
- TABLE 8. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 9. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR IMMUNOASSAY, BY REGION , 2020-2030,($MILLION)
- TABLE 10. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET IMMUNOASSAY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 11. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 12. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)
- TABLE 14. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR DISEASE TESTING, BY REGION , 2020-2030,($MILLION)
- TABLE 15. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET DISEASE TESTING BY COUNTRY, 2020-2030,($MILLION)
- TABLE 16. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR DRUG-RESISTANCE TESTING, BY REGION , 2020-2030,($MILLION)
- TABLE 17. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET DRUG-RESISTANCE TESTING BY COUNTRY, 2020-2030,($MILLION)
- TABLE 18. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)
- TABLE 19. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR HOSPITAL ACQUIRED PNEUMONIA, BY REGION , 2020-2030,($MILLION)
- TABLE 20. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET HOSPITAL ACQUIRED PNEUMONIA BY COUNTRY, 2020-2030,($MILLION)
- TABLE 21. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR BLOODSTREAM INFECTIONS, BY REGION , 2020-2030,($MILLION)
- TABLE 22. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BLOODSTREAM INFECTIONS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 23. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR SURGICAL SITE INFECTIONS, BY REGION , 2020-2030,($MILLION)
- TABLE 24. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SURGICAL SITE INFECTIONS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 25. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR GASTROINTESTINAL INFECTIONS, BY REGION , 2020-2030,($MILLION)
- TABLE 26. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET GASTROINTESTINAL INFECTIONS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 27. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR URINARY TRACT INFECTIONS (UTI), BY REGION , 2020-2030,($MILLION)
- TABLE 28. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET URINARY TRACT INFECTIONS (UTI) BY COUNTRY, 2020-2030,($MILLION)
- TABLE 29. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 30. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 31. GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 32. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION)
- TABLE 33. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 34. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR STANDALONE LABORATORIES, BY REGION , 2020-2030,($MILLION)
- TABLE 35. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET STANDALONE LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
- TABLE 36. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 37. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 38. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 39. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)
- TABLE 40. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)
- TABLE 41. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)
- TABLE 42. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)
- TABLE 43. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 44. NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 45. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 46. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 47. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 48. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 49. U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 50. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 51. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 52. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 53. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 54. CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 55. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 56. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 57. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 58. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 59. MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 60. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)
- TABLE 61. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)
- TABLE 62. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)
- TABLE 63. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)
- TABLE 64. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 65. EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 66. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 67. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 68. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 69. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 70. GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 71. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 72. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 73. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 74. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 75. FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 76. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 77. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 78. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 79. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 80. U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 81. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 82. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 83. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 84. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 85. ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 86. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 87. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 88. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 89. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 90. SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 91. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 92. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 93. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 94. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 95. REST OF EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 96. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)
- TABLE 97. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)
- TABLE 98. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)
- TABLE 99. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)
- TABLE 100. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 101. ASIA-PACIFIC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 102. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 103. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 104. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 105. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 106. JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 107. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 108. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 109. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 110. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 111. CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 112. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 113. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 114. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 115. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 116. AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 117. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 118. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 119. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 120. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 121. INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 122. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 123. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 124. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 125. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 126. SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 127. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 128. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 129. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 130. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 131. REST OF LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 132. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY PRODUCT, 2020-2030,($MILLION)
- TABLE 133. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY TEST TYPE, 2020-2030,($MILLION)
- TABLE 134. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY APPLICATION, 2020-2030,($MILLION)
- TABLE 135. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY BY INFECTION TYPE, 2020-2030,($MILLION)
- TABLE 136. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 137. LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 138. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 139. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 140. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 141. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 142. BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 143. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 144. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 145. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
- TABLE 146. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY INFECTION TYPE 2020-2030,($MILLION)
- TABLE 147. SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
- TABLE 148. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY PRODUCT 2020-2030,($MILLION)
- TABLE 149. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY TEST TYPE 2020-2030,($MILLION)
- TABLE 150. SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET BY BY APPLICATION 2020-2030,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook